TOWNSVILLE, AAP – A new rapid and low-cost COVID test has been developed by a Queensland company with the breakthrough expected to be used worldwide.
The EuGeni COVID-19 Antigen Rapid Test, is a single use and disposable immunochromatographic rapid test intended to be used by healthcare professionals.
Immunochromatographic tests are based on the identification and detection procedures for antigen-antibody immune reactions when tests are conducted.
As part investigations into tests for Sepsis, AnteoTech focused their technology into developing an antigen test that could deliver results within 15 minutes.
Results from the rapid tests identifies the presence or absence of the COVID-19 antigen as an aid in the diagnosis of infection, and has an overall sensitivity of 97.3 per cent and specificity of 99.6 per cent.
Following the launch of the EuGeni testing platform on Wednesday, AnteoTech has been approved for sales across Europe with the aim to enter the US and Australian markets by mid-year.
“This is a major milestone for the company, with our sights set on finalising approvals here in Australia and in the US where our technology is already being used by another Brisbane company (Ellume) to target the home test market,” CEO Derek Thomson said.
The Queensland government has also shown its support, committing a $1.4 million grant to help progress the test through to commercialisation.
Mr Thomson said as well as capturing a large slice of the European rapid test market, AnteoTech was ready to roll out a saliva-based version, ending the need for invasive nasal swabs.
The EuGeni platform could also be used to detect other infections, bacterial and viral conditions.
“We believe we have a superior test with high sensitivity and specificity based on our unique AnteoBindTM technology,” Mr Thomson said.
“We will soon enhance this offering with a saliva use case and new COVID-19/Flu A/FluB Multiplex test, which will give us a very strong competitive advantage over other products currently on the market.”